Navigation Links
New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
Date:3/31/2008

CHICAGO, March 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that preclinical research presented at the American College of Cardiology 57th Annual Scientific Session in Chicago showed that ranolazine increased glucose-stimulated insulin secretion (GSIS) in pancreatic islets isolated from animals and humans.

The Company believes that the increase in GSIS seen with ranolazine may contribute to the statistically significant reductions in hemoglobin A1c (HbA1c) levels observed with Ranexa in cardiovascular patients with diabetes from the phase 3 CARISA (n=189 with angina and diabetes) and MERLIN-TIMI 36 (n=2,220 with acute coronary syndromes and diabetes) clinical trials. In CARISA, Ranexa reduced HbA1c levels by an average of up to 0.7 percentage points. In MERLIN-TIMI 36, Ranexa lowered HbA1c versus placebo by an average of 0.43 percentage points at four months in patients with a mean baseline HbA1c level of 7.5%.

The preclinical results presented today showed that ranolazine increased GSIS in a dose-dependent manner in isolated islets. Acute administration of ranolazine to animals also significantly increased GSIS in the presence of a glucose load (p<0.05). Peak increases in insulin levels from ranolazine were similar to those seen with glibenclamide, a sulfonylurea used as a positive control. Unlike glibenclamide, in the absence of glucose ranolazine did not have any effect on insulin secretion.

"These data provide important additional information on the potential underlying mechanism which may be responsible for significant HbA1c reductions without associated hypoglycemia in both the CARISA and MERLIN-TIMI 36 studies," said Luiz Belardinelli, M.D., senior vice president of pharmaco
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
(Date:11/26/2014)... Scott Steiger lives in St. Louis ... the past 20 years, he,s traveled extensively and prior to that, ... six of the seven continents. Travel is a big part of ... - http://photos.prnewswire.com/prnh/20141126/161077 So when he designs ... of what,s required. His latest creation is the Road ...
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
...   Unigene Laboratories, Inc. (OTCBB: UGNE), ... of peptide-based therapeutics, announced that Ashleigh Palmer, President and ... the Biotech Showcase™ 2012 in San Francisco, CA on ... p.m. ET).  Mr. Palmer,s presentation will include an overview of ...
... Md., Jan. 4, 2012 /PRNewswire-iReach/ -- ... pharmaceutical company focused exclusively in the HIV-1 therapeutic ... to provide medicinal chemistry services to support DFH ... maturation inhibitor drugs. Maturation inhibitors are a novel ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 2DFH Pharma to Collaborate with CiVentiChem to Develop Second-Generation HIV Maturation Inhibitor Drugs 3
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated ... Liebhard LLP reports. , Documents recently updated ... 1,079 records included in the state proceeding, all ... schizophrenia, bipolar disorder and other psychiatric conditions. Many ...
(Date:11/27/2014)... Most babies and young children don,t need medicines if ... Administration says. Over-the-counter (OTC) cold and cough medicine ... because they could cause serious and potentially deadly side ... three colds a year, but children get them more ... to give them pain relievers, decongestants and other medicines, ...
(Date:11/27/2014)... meals can pose a challenge for people who have ... Many traditional Thanksgiving dishes -- such as turkey, corn, ... "when it comes to pies, stuffing, gravy, etc., gluten-free ... director of the Gluten and Allergic Digestive Disorders program ... said in a center news release. "For those ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... Now that Thanksgiving is finally here ... Emassagechair.com has announced its eagerly awaited, once ... , Negotiating on behalf of their customers, and drawing ... Emassagechair.com has generated significant buzz in the industry with ... yet. , Shoppers are excited for significant savings available ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
... News) -- Statins, a class of cholesterol-lowering drugs that includes ... had a certain kind of stroke with unknown cause, a ... young people, and it,s even more uncommon for them to ... the Aug. 2 issue of the journal Neurology , ...
... fecal occult blood test (iFOBT) is effective for predicting ... upper gastrointestinal (GI) tract, confirms a study in ... link only) http://www.cmaj.ca/site/embargo/cmaj101248.pdf . The immunochemical fecal ... screen for bleeding without symptoms in the lower GI ...
... of 1 percent of the microbes that live in the colon, ... gut are fundamental to colon health. In a new study ... where they live and how abundant they are in different parts ... International Society for Microbial Ecology Journal . This is ...
... A novel therapy that reduces elevated blood levels of a ... of pregnancy, may someday address the therapeutic dilemma posed by ... the dangers that early delivery poses to an immature fetus. ... Circulation , a team of U.S. and German researchers ...
... a lower socioeconomic status neighborhood are more likely to ... more affluent neighborhoods, according to a new RAND Corporation study. ... of Public Health , is the largest of its type ... with lower cognitive function. The study found that potential ...
... of Vanderbilt University was awarded a $25,000 grant from ... research in abnormal BCL6 overexpression, which occurs in a ... Vanderbilt University have obtained drugs that inhibit HDAC3another epigenetic ... cancer. Scientists believe that by eliminating BCL6, they can ...
Cached Medicine News:Health News:Statins May Help Heart in Some Young Stroke Patients 2Health News:Noninvasive fecal occult blood test effective screen for lower GI tract lesions 2Health News:Researchers map minority microbes in the colon 2Health News:Researchers map minority microbes in the colon 3Health News:Pilot study suggests new approach to treat preeclampsia 2Health News:Pilot study suggests new approach to treat preeclampsia 3Health News:Neighborhood status influences older women's cognitive function, study finds 2
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... CVMstat® provides leading ... of topics involving all ... including sections on diagnosis ... arterial and venous disease. ...
... to the management of common ... a response from leading experts ... more common, and often poorly ... It is a "how-to" guide ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: